查找临床试验
已按「骨髓增生异常综合征」检索，对应国际通用词 myelodysplastic syndrome
共找到 12 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 10:03，每 5 分钟自动同步Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment
China
年龄 18 Years – 70 Years
Haisco Pharmaceutical Group Co., Ltd.
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
China
年龄 16 Years – 55 Years
Shanghai Jiao Tong University School of Medicine
Predictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow Cytometry
China
年龄 15 Years – 70 Years
Peking University People's Hospital
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
United States、Belgium、Canada、France、Italy 等 12 国
年龄 12 Years – 不限
Sumitomo Pharma America, Inc.
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
United States、Australia、China
年龄 18 Years – 不限
Beijing InnoCare Pharma Tech Co., Ltd.
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
United States、China
年龄 18 Years – 不限
Akeso
Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT
China
年龄 12 Years – 65 Years
Peking University People's Hospital
Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
China
年龄 18 Years – 75 Years
Wuhan Createrna Science and Technology Co., Ltd
Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation
China
年龄 18 Years – 不限
Institute of Hematology & Blood Diseases Hospital, China
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
Canada、Colombia、Hungary、India、Italy 等 12 国
年龄 18 Years – 不限
Regeneron Pharmaceuticals
Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement
China
年龄 18 Years – 55 Years
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants
China
年龄 18 Years – 55 Years
Shenzhen Kangzhe Biotechnology Co., Ltd.